Dec 15 (Reuters) - CSL Ltd (CSL) :
- GARADACIMAB RECEIVES FDA AND EMA FILING ACCEPTANCE
- ORPHAN-DRUG DESIGNATION FOR GARADACIMAB AS A THERAPY FOR HEREDITARY ANGIOEDEMA GRANTED BY BOTH FDA AND EMA
(([email protected];))
News: CSL CSL Ltd Says Garadacimab Received FDA And EMA Filing Acceptance
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$254.99 |
Change
6.600(2.66%) |
Mkt cap ! $123.6B | |||
| Open | High | Low | Value | Volume |
| $252.00 | $256.17 | $251.10 | $212.7M | 825.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 92 | $254.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $255.02 | 7 | 3 |
View Market Depth
| Last trade - 12.04pm 18/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |